89bio Inc (ETNB)
8.61
-0.36
(-4.01%)
USD |
NASDAQ |
May 17, 16:00
8.61
0.00 (0.00%)
Pre-Market: 20:00
89bio SG&A Expense (Quarterly): 9.849M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 9.849M |
December 31, 2023 | 7.614M |
September 30, 2023 | 7.928M |
June 30, 2023 | 7.214M |
March 31, 2023 | 6.218M |
December 31, 2022 | 6.298M |
September 30, 2022 | 4.844M |
June 30, 2022 | 5.052M |
March 31, 2022 | 5.259M |
December 31, 2021 | 5.262M |
September 30, 2021 | 4.622M |
June 30, 2021 | 4.921M |
Date | Value |
---|---|
March 31, 2021 | 4.608M |
December 31, 2020 | 3.777M |
September 30, 2020 | 3.225M |
June 30, 2020 | 3.23M |
March 31, 2020 | 2.924M |
December 31, 2019 | 2.419M |
September 30, 2019 | 1.518M |
June 30, 2019 | 0.834M |
March 31, 2019 | 0.523M |
December 31, 2018 | 0.716M |
September 30, 2018 | 0.497M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
0.834M
Minimum
Jun 2019
9.849M
Maximum
Mar 2024
4.881M
Average
4.882M
Median
SG&A Expense (Quarterly) Benchmarks
Akero Therapeutics Inc | 9.304M |
Madrigal Pharmaceuticals Inc | 80.80M |
Viking Therapeutics Inc | 9.97M |
Galectin Therapeutics Inc | 1.594M |
Terns Pharmaceuticals Inc | 6.859M |